Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
3.33 (USD) • At close December 27, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Atea Pharmaceuticals, Inc. |
Symbool | AVIR |
Munteenheid | USD |
Prijs | 3.33 |
Beurswaarde | 281,262,123 |
Dividendpercentage | 0% |
52-weken bereik | 2.75 - 4.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jean-Pierre Sommadossi Ph.D. |
Website | https://ateapharma.com |
An error occurred while fetching data.
Over Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)